The MetAction study (PIs: Ree, Flatmark, Dueland, Mælandsmo), funded in part by the Research Council of Norway [Grant 218325], is based on the notion that metastatic lesions do not necessarily harbor the same molecular aberrations as the patient’s primary tumor. Hence, in patients with advanced disease, biopsies will be collected from metastatic lesions (on progression on established therapy) for identification of actionable drug targets. The trial started accrual in May 2014: Applying the N-of-1 study design, a targeted drug will be offered following target verification, and clinical, radiologic, and molecular treatment responses will be recorded. Of note, individualization of therapies based on readouts from high-throughput genomic and proteomic analyses requires a change in the traditional organization of the clinical team in charge of patient management. An important aim of the study is therefore to establish necessary infrastructure, educate multidisciplinary teams, and gain experience in trial 9 design and conduct of patient-adapted treatment, thereby creating a foundation for personalized cancer medicine in Norway. We envisage output information that may provide recommendations or guidelines on the optimized implementation of such treatment strategies. Clinical–translational research requires stringent and validated methodologies and disease models for the elucidation of disease mechanisms. As outlined above, the network has access to most genomic and proteomic high-throughput technologies through core facilities, to recent and emerging technological equipment for functional MRI diagnostics, to required small-animal facilities (including that for MRI applications), and to an experimental radiobiology facility. Importantly, we have long-term experience in using experimental in vitro and in vivo CRC models.
“From Bed to Bench to Byte to Bedside” Background: Intratumoral heterogeneity may cause therapeutic failure. Currently, cancer treatment is based upon primary tumor characteristics, and metastatic cells having other molecular properties may tolerate this therapy and result in tumor relapse.
Aim: Indentify actionable targets in the metastatic lesions and thereby offer personalized targeted therapy against metastatic cancer.